Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802044 | 0.98 | CPB2 (0.47) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL29801990 | 0.97 | CPB2 (0.46) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL31688033 | 0.97 | CPB2 (0.47) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL29802039 | 0.92 | GHSR (0.43) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL29802071 | 0.92 | GHSR (0.43) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL29368001 | 0.91 | REN (0.47) | CPB2DPP7 | |
| SCHEMBL8729043 | 0.90 | CPB2 (0.46) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL29381549 | 0.90 | CPB2 (0.46) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL23303426 | 0.89 | MEN1 (0.48) | CPB2DPP7MEN1KMT2AGHSR | |
| SCHEMBL23303428 | 0.89 | MEN1 (0.48) | CPB2DPP7MEN1KMT2AGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403653-B | D (+) -beta- (3, 4-dihydroxyphenyl) -lactoyl-Pro-Ala-Lys, synthesis and application thereof | 首都医科大学 | 2024-08-06 | — | — | CN | claimed |
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | claimed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | claimed |
| CN-112175041-B | Ethyl QRPAK modified bis-carbolino piperazine diketone and preparation, activity and application thereof | 首都医科大学（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-115403653-A | D (+) -beta- (3, 4-dihydroxyphenyl) -lactyl-Pro-Ala-Lys, synthesis and application thereof | 首都医科大学 | 2022-11-29 | — | — | CN | claimed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | claimed |
| CN-112094318-B | Ethyl RPAK modified bis-carbolino-piperazinediones, preparation, activity and use thereof | 首都医科大学 | 2022-09-02 | — | — | CN | claimed |
| CN-110577574-B | 1S-methyl-beta-tetrahydrocarboline acyl-K (PAK) -RGDV, and synthesis, activity and application thereof | 首都医科大学 | 2022-08-09 | — | — | CN | claimed |
| CN-112010936-B | Ethyl GRPAK modified bis-carbolino piperazine diketone and preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| CN-111995661-B | Ethyl ARPAK modified bis-carbolino-piperazinediones, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| CN-112010928-B | Ethyl PAK modified bis-carbolino-piperazinedione, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| EP-4313104-B1 | DC009 FOR TREATING ACUTE ISCHEMIC STROKE | LUMOSA THERAPEUTICS CO LTD (TW) | 2026-05-13 | — | — | EP | disclosed |
| EP-4516288-A3 | PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE | Lumosa Therapeutics Co., Ltd. (TW) | 2025-06-18 | — | — | EP | disclosed |
| US-20250186534-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE | LUMOSA THERAPEUTICS CO., LTD (TW) | 2025-06-12 | — | — | US | disclosed |
| US-20250186534-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE | LUMOSA THERAPEUTICS CO., LTD (TW) | 2025-06-12 | — | — | US | disclosed |
| US-11338008-B2 | Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate | LUMOSA THERAPEUTICS CO., LTD (TW) | 2022-05-24 | — | — | US | disclosed |
| CN-112010936-B | Ethyl GRPAK modified bis-carbolino piperazine diketone and preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-111995661-B | Ethyl ARPAK modified bis-carbolino-piperazinediones, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-112010928-B | Ethyl PAK modified bis-carbolino-piperazinedione, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-112010928-B | Ethyl PAK modified bis-carbolino-piperazinedione, preparation, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186534-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE | PCSK9, SERPINC1, DDOST | CPB2 78/4885DPP7 269/4885MEN1 308/4885 |
| US-11338008-B2 | Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate | PCSK9, SERPINC1, DDOST | CPB2 78/4885DPP7 269/4885MEN1 308/4885 |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | CPB2 397/4885DPP7 2122/4885MEN1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.